Cancers, Vol. 16, Pages 1291: Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT
Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting. (Source: Cancers)
Source: Cancers - March 26, 2024 Category: Cancer & Oncology Authors: Julie F. M. Geerts Charl ène J. van der Zijden Pieter C. van der Sluis Manon C. W. Spaander Grard A. P. Nieuwenhuijzen Camiel Rosman Hanneke W. M. van Laarhoven Rob H. A. Verhoeven Bas P. L. Wijnhoven Sjoerd M. Lagarde Bianca Mostert Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1269: Sperm-Associated Antigen 5 Knockout Reduces Doxorubicin and Docetaxel Resistance in Triple-Negative Breast Cancer MDA-MB-231 and BT549 Cells
In conclusion, recombinant plasmid-based CRISPR-Cas9 technology can be used to delete the SPAG5 gene in the TNBC cell lines. SPAG5 has an important role in regulating cell proliferation and doxorubicin- and docetaxel-resistance in MDA-MB-231 and BT549 cells. (Source: Cancers)
Source: Cancers - March 24, 2024 Category: Cancer & Oncology Authors: Ji He Jiawei Li Yanbiao Liu Yan Li Tags: Article Source Type: research
Development of a novel prostate Cancer-Stroma Sphere (CSS) model for In Vitro tumor microenvironment studies
Transl Oncol. 2024 Mar 22;44:101930. doi: 10.1016/j.tranon.2024.101930. Online ahead of print.ABSTRACTTumor employs non-cancerous cells to gain beneficial features that promote growth and survival of cancer cells. Despite intensive research in the area of tumor microenvironment, there is still a lack of reliable and reproducible in vitro model for tumor and tumor-microenvironment cell interaction studies. Herein we report the successful development of a heterogeneous cancer-stroma sphere (CSS) model composed of prostate adenocarcinoma PC3 cells and immortalized mesenchymal stem cells (MSC). The CSS model demonstrated a str...
Source: Translational Oncology - March 23, 2024 Category: Cancer & Oncology Authors: Aigul R Rakhmatullina Maria A Zolotykh Yulia V Filina Rimma N Mingaleeva Aisylu R Sagdeeva Eugenia A Boulygina Dina U Gafurbaeva Emil R Bulatov Albert A Rizvanov Regina R Miftakhova Source Type: research
Development of a novel prostate Cancer-Stroma Sphere (CSS) model for In Vitro tumor microenvironment studies
Transl Oncol. 2024 Mar 22;44:101930. doi: 10.1016/j.tranon.2024.101930. Online ahead of print.ABSTRACTTumor employs non-cancerous cells to gain beneficial features that promote growth and survival of cancer cells. Despite intensive research in the area of tumor microenvironment, there is still a lack of reliable and reproducible in vitro model for tumor and tumor-microenvironment cell interaction studies. Herein we report the successful development of a heterogeneous cancer-stroma sphere (CSS) model composed of prostate adenocarcinoma PC3 cells and immortalized mesenchymal stem cells (MSC). The CSS model demonstrated a str...
Source: Translational Oncology - March 23, 2024 Category: Cancer & Oncology Authors: Aigul R Rakhmatullina Maria A Zolotykh Yulia V Filina Rimma N Mingaleeva Aisylu R Sagdeeva Eugenia A Boulygina Dina U Gafurbaeva Emil R Bulatov Albert A Rizvanov Regina R Miftakhova Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Methods of Information in Medicine - March 22, 2024 Category: Information Technology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Clinical Prostate Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells
In conclusion, in this study, we demonstrated how the combination of β-LP and HT could offer an affordable, safe, and effective approach against TNBC.PMID:38518601 | DOI:10.1016/j.biopha.2024.116439 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 22, 2024 Category: Drugs & Pharmacology Authors: Jes ús Calahorra Jos é L Blaya-Cánovas Olivia Castellini-P érez Ernesto Aparicio-Puerta Candela Cives-Losada Jose J G Marin Markel Rementeria Francisca E Cara Araceli L ópez-Tejada Carmen Gri ñán-Lisón Francesco Aulicino Imre Berger Juan A Marchal Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Methods of Information in Medicine - March 22, 2024 Category: Information Technology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Clinical Prostate Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells
In conclusion, in this study, we demonstrated how the combination of β-LP and HT could offer an affordable, safe, and effective approach against TNBC.PMID:38518601 | DOI:10.1016/j.biopha.2024.116439 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 22, 2024 Category: Drugs & Pharmacology Authors: Jes ús Calahorra Jos é L Blaya-Cánovas Olivia Castellini-P érez Ernesto Aparicio-Puerta Candela Cives-Losada Jose J G Marin Markel Rementeria Francisca E Cara Araceli L ópez-Tejada Carmen Gri ñán-Lisón Francesco Aulicino Imre Berger Juan A Marchal Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Methods of Information in Medicine - March 22, 2024 Category: Information Technology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Methods of Information in Medicine - March 22, 2024 Category: Information Technology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Methods of Information in Medicine - March 22, 2024 Category: Information Technology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Methods of Information in Medicine - March 22, 2024 Category: Information Technology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
